Amendment: SEC Form SC 13G/A filed by Caribou Biosciences Inc.
$CRBU
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/3/2024 | $13.00 → $3.00 | Outperform → In-line | Evercore ISI |
| 11/8/2023 | Neutral | Cantor Fitzgerald | |
| 10/31/2023 | $13.00 | Outperform | Evercore ISI |
| 7/11/2023 | $23.00 | Buy | Truist |
| 2/18/2022 | $22.00 | Outperform | RBC Capital |
| 2/14/2022 | $19.00 | Buy | Brookline Capital |
| 12/1/2021 | $36.00 | Outperform | Oppenheimer |
| 11/30/2021 | $28.00 | Buy | H.C. Wainwright |
BERKELEY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in the following investor conferences: Citi's 2024 Global Healthcare Conference, Miami, FL December 3, 2024, panel at 2:30 PM ESTPanel title: Cell therapies in autoimmune disordersWebcast 7th Annual Evercore ISI HealthCONx Conference, Coral Gables, FLDecember 4, 2024, fireside chat at 10:25 AM ESTWebcast For more information, visit the Events page on Caribou's website. Webcasts will be available on the Caribou website fo
-- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple clinical data reports planned for 2025 -- -- Enrolling patients with LBCL (2L and after prior CD19-targeted therapies) with HLA matching strategy in CB-010 ANTLER Phase 1 trial; next data report planned for H1 2025 -- -- Continuing dose escalation portion of the CB-011 CaMMouflage Phase 1 trial in r/r MM with higher lymphodepletion regimen following observations of efficacy; dose escalation data to be presented H1 2025 -- -- $281.0 million in cash, cash equivalents, and marketable securities expected to fund the current operating plan into H2 2026 -- BERKELEY, Calif., Nov. 06, 2024
BERKELEY, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract has been accepted for a poster presentation at the American College of Rheumatology (ACR) Convergence 2024, which will be held November 14-19, 2024 in Washington, DC. The poster will highlight the preclinical data and key elements of the clinical trial design that supported the investigational new drug (IND) clearance to evaluate CB-010 in the GALLOP Phase 1 clinical trial in patients with lupus nephritis (LN) and extrarenal lupus (ERL). Details of the poster presentation are as follows: Title:
In the last three months, 4 analysts have published ratings on Caribou Biosciences (NASDAQ:CRBU), offering a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 2 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $15.25, a high estimate of $24.00, and a low estimate of $9.00. This current average represents a 19.74%
HC Wainwright & Co. analyst Robert Burns reiterates Caribou Biosciences (NASDAQ:CRBU) with a Buy and maintains $9 price target.
- Reuters
SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)
SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)
SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)
10-Q - Caribou Biosciences, Inc. (0001619856) (Filer)
8-K - Caribou Biosciences, Inc. (0001619856) (Filer)
8-K/A - Caribou Biosciences, Inc. (0001619856) (Filer)
3 - Caribou Biosciences, Inc. (0001619856) (Issuer)
4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
3 - Caribou Biosciences, Inc. (0001619856) (Issuer)
Evercore ISI downgraded Caribou Biosciences from Outperform to In-line and set a new price target of $3.00 from $13.00 previously
Cantor Fitzgerald initiated coverage of Caribou Biosciences with a rating of Neutral
Evercore ISI initiated coverage of Caribou Biosciences with a rating of Outperform and set a new price target of $13.00
-- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Tina Albertson, MD, PhD, as chief medical officer. Dr. Albertson brings 15 years of experience leading clinical drug development of cellular therapies and biologics. She will be responsible for strategic leadership of the clinical, regulatory, and medical affairs functions, and provide medical and operational leadership of Caribou's four clin
-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Terri Laufer, MD, to its scientific advisory board. Dr. Laufer is a leading rheumatologist known for her extensive research into immune cell regulation and dysfunction that leads to autoimmune diseases. She is an emeritus associate professor of medicine at the Perelman School of Medicine at the University of Pennsylvania and an attending rheumatologist at the Penn Presbyterian Med
-- Dr. Jagannath is a renowned expert in the research and treatment of multiple myeloma -- BERKELEY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sundar Jagannath, MD, to its scientific advisory board. With four decades of experience, Dr. Jagannath is a renowned expert in bone marrow transplantation and treating patients with multiple myeloma, and he is the director of the Center of Excellence for Multiple Myeloma at The Tisch Cancer Institute and professor of medicine, hematology and medical oncology, at Mount Sinai School of Medicine, New Yo
-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) -- -- Plan to enroll ~20 additional 2L LBCL patients in ANTLER to confirm that partial HLA matching improves patient outcomes; initial data expected in H1 2025 -- -- Caribou expects to initiate a pivotal trial for CB-010 in H2 2025, upon confirmation of improved outcomes in partially HLA matched cohort -- -- Off-the-shelf CB-010 is partially HLA matched to patient within current screening timelines -- -- KOL webcast discussion of data from 46
-- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases -- -- Advancing ANTLER Phase 1 trial for 2L LBCL; initial dose expansion data to be shared at a medical congress in Q2 2024 -- -- Conference call and webcast scheduled for today at 5:00 pm ET -- BERKELEY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, t
-- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies -- -- 94% overall response rate (ORR), 69% complete response (CR) rate, and 44% CR rate at ≥6 months following a single dose of CB-010; 24 months is the longest CR maintained to date -- -- LBCL patient subgroup had a 50% CR rate at ≥6 months; 18 months is the longest LBCL subgroup CR maintained to date -- -- Actively enrolling second-line LBCL patients in ANTLER dose expansion -- -- Conference call and webcast scheduled for today at 4:30 pm ET -- BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-s